UMIP seeks co-development partner for TSG-6 bone disease candidate

Press/Media: Research

Description

PharmaTimes article

Period7 Sep 2010

Media coverage

1

Media coverage

  • TitleUMIP seeks co-development partner for TSG-6 bone disease candidate
    Degree of recognitionNational
    Media name/outletPharma Times
    Media typeWeb
    Country/TerritoryUnited Kingdom
    Date7/09/10
    DescriptionThe University of Manchester in the UK is looking for a commercial partner or partners to co-develop a novel protein-based treatment that “could be of major benefit” in bone diseases such as osteoporosis.
    The call comes from the university’s intellectual property commercialisation company, UMIP, which has a 12-month licence under an exclusive option from the University of Oxford to conduct further research with TSG-6, a human protein produced by the body at sites of inflammation, and to take the technology forward into global markets.
    Producer/AuthorPeter Mansell
    URLwww.pharmatimes.com/news/umip_seeks_co-development_partner_for_tsg-6_bone_disease_candidate_982489
    PersonsAnthony Day, Caroline Milner